Compare CATO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | IMMP |
|---|---|---|
| Founded | 1946 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.0M | 54.4M |
| IPO Year | 1994 | 2012 |
| Metric | CATO | IMMP |
|---|---|---|
| Price | $3.19 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 72.9K | ★ 618.4K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $653,812,000.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | ★ 0.62 | N/A |
| 52 Week Low | $2.59 | $0.29 |
| 52 Week High | $4.92 | $3.53 |
| Indicator | CATO | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 42.05 |
| Support Level | $2.80 | $0.35 |
| Resistance Level | $3.27 | $0.39 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.58 | 60.33 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.